Contrast Injector Solutions (CIS) provides replacement components for high-failure applications in late-model and end of life injectors and is actively expanding its product portfolio beyond these critical wear items. The company’s long-term strategy is to increase coverage across additional injector platforms by supporting a broader range of manufacturers, introducing components for new injector models and expanding overall serviceable part availability to meet evolving market demands. Through these efforts, CIS aims to reduce laboratory downtime, extend the operational service life of injector systems and provide customers with cost-effective solutions that improve equipment reliability and long-term performance.
TechNation recently had the opportunity to interview CIS founder and CEO Jonathan Clarke about the company and plans for the future.
Q: HOW DOES YOUR COMPANY STAND OUT IN THE MEDICAL EQUIPMENT FIELD?
CLARKE: Clarke has long been a trusted name in the injector industry, with decades of experience supporting injector testing, service and repair. Our goal is to leverage that expertise and reputation to deliver high-quality, cost-effective replacement components that extend the operational life of end-of-life injector systems and help customers maximize the value of their existing equipment.
We recognize that sourcing replacement parts for legacy injector platforms can be challenging due to the limited number of qualified suppliers. By applying Clarke’s engineering expertise, supplier network and technical resources, we are committed to identifying, developing and sourcing hard-to-find components that keep end-of-life injectors operating reliably for years to come.
Q: WHAT IS ON THE HORIZON FOR YOUR COMPANY? DO YOU HAVE ANY GOALS YOU WOULD LIKE TO ACHIEVE IN THE NEAR FUTURE?
CLARKE: CIS is committed to keeping late-model contrast injectors operational by providing reliable replacement components that support continued system performance. Equipment downtime can disrupt clinical workflows, impact patient care and result in significant replacement costs. Supporting end-of-life injector platforms with dependable parts solutions is essential to maximizing equipment availability and extending system service life.
Looking ahead, CIS is focused on building a nationwide service network through strategic partnerships with qualified service providers. By combining a trusted service network with high-quality CIS replacement components, we aim to deliver a comprehensive, cost-effective support solution that helps healthcare providers maintain critical injector systems well beyond their original service life.
Q: IS THERE ANYTHING ELSE YOU WOULD LIKE TECHNATION READERS TO KNOW?
CLARKE: CIS is a veteran-owned and operated company with more than 14 years of hands-on experience servicing injector systems from the industry’s leading manufacturers, including Bayer/Medrad, ACIST/Bracco and Mallinckrodt/Liebel-Flarsheim. This experience has given us a deep understanding of the operational demands hospitals and imaging labs face, and the critical importance of minimizing equipment downtime to support uninterrupted patient care.
We recognize that injector failures require an immediate response, and that the urgency of these situations is often underestimated in the industry. Our commitment is to provide high-quality, cost-effective replacement parts and responsive support that restore equipment quickly, maximize system uptime and extend the service life of end-of-life injector platforms. Through technical expertise, dependable products and customer-focused service, CIS delivers practical solutions healthcare providers can rely on.
For more information, visit injector-solutions.com
